Abstract
The prevention and chemoprevention of cancer is based on identifying a pre-neoplastic lesion and altering the outcome by early intervention. Many of the gastrointestinal epithelial cancers are related to chronic inflammatory conditions for many years prior to cancer development. It is clear that treatment of the inflammatory condition can prevent and indeed reverse changes that predispose to cancer. This is most notable for helicobacter pylori infection of the stomach. Screening for Barrett’s oesophagus and other conditions are more controversial and the results of large scale clinical trials are awaited. Nevertheless preventive strategies are highly attract health care interventions and are being actively considered.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allum WH, Griffin SM, Watson A, Colin-Jones D (2002) Guidelines for the management of oesophageal and gastric cancer. Gut 50 (suppl V):v1–v23
Barr H (2008) Squamous cell carcinoma of the oesophagus. In: Jankowski J, Sampliner RE, Kerr DJ, Fung Y (eds) Gastrointestinal oncology: a critical multidisciplinary team approach. Oxford University Press, Oxford
Bini EJ, Green B, Poles MA (2009) Screening colonoscopy for detection of neoplastic lesions in asymptomatic HIV-infected subjects. Gut 58:1129–1134
Brown L, Devesa S, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100:1184–1187
Cairns S, Scholefield JH (2002) Guidelines for colorectal cancer screening in high risk groups. Gut 51(Suppl V):v1–v2
Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohns disease. Aliment Pharmacol Ther 23:1097–1104
Choi KS, Kwak M-S, Lee H-Y, Jun JK, Hahm M, Par E-C (2009) Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. Cancer Epidemiol Biomarkers Prev 18:1390–1398
Clemons NJ, McColl KE, Fitzgerald R (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett’s carcinogenesis via distinct mechanisms. Gastroenterology 133:1198–1209
Das D, Ishaq S, Harrison R, Kosuri K, Harper E, deCaestecker J, Sampliner R, Barr H, Watson P, Moayyedi PJ, Jankowski J (2008) Management of Barrett’s esophagus in the UK: over treated and under biopsied but improved by the introduction of a national randomised trial. AJG 103:1079–1089
Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis:a meta-analysis. Gut 48:526–535
Ekbom A, Helmick C, Zack M et al (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228–1233
Fernando HC, Murthy SC, Hofstetter W et al (2009) The society of thoracic surgeons practice guideline series: Guidelines for the management of Barrett’s esophagus with high-grade dysplasia. Ann Thorac Surg 87:1993–2002
Friedman S (2006) Cancer in Crohns disease. Gastroenterol Clin N Am 35:621–639
Fukase K, Kato M, Kikuchi S et al (2008) Effect of eradication of helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic restion of gastric cancer: an open-label, randomised controlled trial. Lancet 372:392–397
Graham DY, Shiotani A (2005) The time to eradicate gastric cancer is now. Gut 54:735–738
Grosjean P, Monnier P (1998) Photodynamic therapy and mucosectomy for early squamous cell carcinomas in the oesophagus and tracheobronchial tree. Eur J Surg Oncol 24:234
Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, Sobue T (2008) The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 38:259–267
Heath EI, Canto MI, Piantadosi S et al (2007) Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99:545–557
Jankowski J, Barr H (2006) Improving surveillance for Barrett’s oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 332:1512
Jankowski J, Hawk E (2006) A methodological analysis of chemoprevention in the gastrointestinal tract. Nat Clin Pract Gastro Hep 3:101–111
Jess T, Loftus E, Velayos F et al (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted, Minnesota. Gastroenterology 130:1039–1046
Katz P (2008) Esophageal carcinoma and achalasia: another call for screening? Achalasia complicated by squamous cell carcinoma: A prospective study in 195 patients. AJG 88:783–793
Konda A, Duffy MC (2008) Surveillance of patients at increased risk of colorectal cancer: inflammatory bowel disease and other conditions. Gastroenterol Clin N Am 37:191–213
Lagergren J, Bergstrom R, Lindgren A, Myren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 18:825–831
Leung WK, Wu M, Kakugawa Y et al (2008) Screening for gastric cancer: current evidence and practice. Lancet Oncol 9:279–287
Logan RFA (2009) Malignancy in unrecognised coeliac disease: a nail in the coffin for mass screening? Gut 58:618–619
Lohi S, Mäki M, Montonen J, Knekt P, Pukkala E, Reunanen A, Kaukinen K (2009) Malignancies in cases with screening—identified evidence of celiac disease: a long-term population-based cohort study. Gut 58:643–647
Marx J (2004) Inflammation and cancer: the link grows stronger. Science 306:966–968
Quante M, Wang TC (2008) Inflammation and stem cells in gastrointestinal carcinogenesis. Physiology 23:350–359
Raj A, Jankowski J (2004) Acid suppression and chemoprevention in Barrett’s oesophagus. Dig Dis 22:171–180
Rieger MA, Hoppe PS, Smejkal BM, Eitelhuber AC, Schroeder T (2009) Hematopoietic cytokines can instruct lineage choice. Science 325:217–218
Rubin DT, Kavitt RT (2006) Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin N Am 35:581–604
Sandler RS, Nyren O, Ekhom A et al (1992) The risk of esophageal cancer in patients with achalasia: a population based study. JAMA 274:1359–1362
Soetikno RM, Lin OS, Heidenreich PA et al (2002) Increased risk of colorectal neoplasia in patients with primary sclersoing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56:48–54
Suzuki H, Iijima K, Scobie C, Fyfe V, Mc Coll KEL (2005) Nitrate and nitrosative chemistry within Barrett’s oesophagus during acid reflux. Gut 54:1527–1535
Tomizawa Y, Wang KK (2009) Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin N Am 38:59–73
Velayos FS, Loftus EV Jr, Jess T et al (2006) predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-controlled study. Gastroenterology 130:1941–1949
Wang K, Sampliner R (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. AJG 103:788–797
Watabe H, Mitsushima T, Yamaji Y et al (2005) Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54:764–768
Wong A, Fitzgerald RC (2005) Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 3:1–10
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Velag Berlin Heidelberg
About this chapter
Cite this chapter
Barr, H. (2011). Gastrointestinal Cancer: Current Screening Strategies. In: Jankowski, J. (eds) Inflammation and Gastrointestinal Cancers. Recent Results in Cancer Research, vol 185. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-03503-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-03503-6_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-03502-9
Online ISBN: 978-3-642-03503-6
eBook Packages: MedicineMedicine (R0)